Sodium valproate tablets

This product is an anti-epileptic drug. Its mechanism of action has not been fully elucidated. Experiments show that this product can increase the synthesis of GABA and reduce the degradation of GABA, thereby increasing the concentration of the inhibitory neurotransmitter g-aminobutyric acid (GABA), reducing the excitability of neurons and inhibiting seizures. In electrophysiological experiments, it was found that this product can produce an inhibitory effect on Na channels similar to phenytoin. It is harmful to the liver.

Valproic acid

This product is white tablets

It is mainly used for the treatment of simple or complex absence seizures, myoclonic seizures, generalized tonic-clonic seizures (grand mal seizures), and sometimes has a certain effect on complex partial seizures. It can be used for various types of epilepsy, especially grand mal seizures and myoclonic epilepsy, febrile convulsions, intractable hiccups, migraines, especially migraines without aura, acute mania, and is effective for panic, anxiety, etc. or withdrawal syndrome in large doses.

Common dosage for adults: 15 mg/kg per day or 600-1200 mg per day divided into 2-3 times. Start with 5-10 mg/kg, increase gradually after one week until the attack can be controlled. When the daily dosage exceeds 250 mg, it should be taken in divided doses to reduce gastrointestinal irritation. The maximum daily dosage is no more than 30 mg/kg per day, or 1.8-2.4 g per day. Common dosage for children: The same as that for adults, 20-30 mg/kg per day, divided into 2-3 times or 15 mg/kg per day, increase by 5-10 mg/kg every other week as needed, until effective or intolerable.

1. Common adverse reactions include diarrhea, indigestion, nausea, vomiting, gastrointestinal spasm, and changes in the menstrual cycle; 2. Less common are transient hair loss, constipation, drowsiness, dizziness, fatigue, headache, ataxia, mild tremor, abnormal excitement, restlessness and irritability; 3. Long-term use may occasionally cause pancreatitis and acute liver necrosis; 4. It may cause thrombocytopenia, leading to purpura, bleeding and prolonged bleeding time, and blood tests should be conducted regularly; 5. It may damage liver function, causing elevated serum alkaline phosphatase and aminotransferase, and liver function should be checked after 2 months of use; 6. Occasionally there may be allergies; 7. Occasionally there may be hearing loss and reversible hearing damage.

Patients with a personal or family history of drug-induced jaundice, liver disease or obvious liver damage are contraindicated. Patients with blood disease, liver disease history, renal damage, or organic encephalopathy should use with caution.

Precautions for children: This product can accumulate in developing bones, so be careful. Precautions for pregnancy and lactation: This drug can pass through the placenta, and there are reports of teratogenicity in animal experiments. Pregnant women should weigh the pros and cons and use it with caution. This product can also be secreted into breast milk, with a concentration of 1-10% of the maternal blood drug. It should be used with caution. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

1 Drinking alcohol can increase the sedative effect. 2 When general anesthetics or central nervous system depressants are used in combination with valproic acid, the clinical effect of the former may be more obvious. 3 When used in combination with anticoagulants such as warfarin or heparin, as well as thrombolytics, it may increase the effect of anticoagulants; valproic acid can cause hypoprothrombinemia and inhibit platelet aggregation. When anticoagulants or thrombolytics are given, the risk of bleeding increases. 4 When used in combination with aspirin or dipyridamole, it can prolong bleeding time due to reduced platelet aggregation. 5 When used in combination with phenobarbital drugs, the latter's metabolism slows down and the blood drug concentration increases, thereby increasing the sedative effect and causing drowsiness. 6 When used in combination with primidone, it can also cause an increase in blood drug concentration and lead to poisoning. If necessary, the dosage of primidone needs to be reduced. 7 When used in combination with clonazepam to prevent and treat absence seizures, there have been reports of a few cases where it has induced absence states. 8 When used in combination with phenytoin, the competition with protein binding may change the blood concentration of both drugs. Since the concentration of phenytoin varies greatly, it needs to be measured frequently, but whether the dosage needs to be adjusted depends on the clinical situation and blood concentration. 9 When used in combination with carbamazepine, the induction of liver enzymes can accelerate drug metabolism, which can reduce the blood concentration and half-life of both drugs. Therefore, it is necessary to monitor the blood concentration to determine whether the dosage needs to be adjusted. 10 When used in combination with drugs that are toxic to the liver, there is a potential risk of liver poisoning. Long-term use in patients with a history of liver disease requires regular liver function checks. 11 When used in combination with haloperidol, loxapine, maprotiline, monoamine oxidase inhibitors, phenothiazines, thioxanthenes and tricyclic antidepressants, it can increase the inhibition of the central nervous system, reduce the convulsion threshold and the effect of valproic acid, and the dosage needs to be adjusted in time to control seizures. Salicylic acid can inhibit the metabolism of valproate, prolonging its half-life, and the combination of the two can affect blood coagulation and platelet function. Salicylic acid cannot be used in combination with valproate in children to avoid Reye syndrome. Naproxen interferes with the protein binding of valproate. The combination of erythromycin and valproate is prone to toxic symptoms of valproate. Carbamazepine, phenytoin, and phenobarbital can reduce serum valproate concentrations; and valproate inhibits phenobarbital metabolism, which increases phenobarbital blood concentrations. The combination of valproate with clonazepam, nitrazepam, etc. can aggravate drowsiness. Taking the antimalarial drug mefloquine can greatly reduce the blood concentration of valproate. The bioavailability of valproate preparations is increased after using aluminum hydroxide or magnesium hydroxide, and other antacids are not effective. Cimetidine prolongs the half-life of valproate, while ranitidine does not have this effect. Avoid using it in combination with aspirin and warfarin.

Keep away from light, store in a sealed dry place

0.2g

30 months.

Beijing Saier Biological Pharmaceutical Co., Ltd.

• Founded in:

  2002-10-24

• Address:

  No. 35, Keyuan Road, Industrial Development Zone, Daxing District, Beijing

• Tax NO.:

  91110115742602836G

• Registered Funds:

  28 million yuan

• Website:

  Log in to view

• Email:

  Log in to view